Filing Details
- Accession Number:
- 0001209191-14-073973
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-09 17:48:11
- Reporting Period:
- 2014-12-05
- Filing Date:
- 2014-12-09
- Accepted Time:
- 2014-12-09 17:48:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1328143 | Adamas Pharmaceuticals Inc | ADMS | Pharmaceutical Preparations (2834) | 421560076 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1604572 | Natalie Mcclure | C/O Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 750 Emeryville CA 94608 | Svp, Product Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-12-05 | 2,000 | $1.76 | 2,840 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-12-05 | 2,000 | $14.01 | 840 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2014-12-05 | 2,000 | $0.00 | 2,000 | $1.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 24,666 | 2020-03-03 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $14.00 to $14.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The Option shares vested according to the following schedule: one-fifth (1/5th) of the shares vest one year after January 4, 2010; the balance of the shares vest in a series of forty-eight (48) successive equal monthly installments measured from the first anniversary of January 4, 2010, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.
Billionaire Hedge Funds
